



January 21, 2026

MEDICAL SPECIALTY DRUG PREAUTHORIZATION REQUIREMENTS

Use this list for the lines of business in the columns below: Commercial managed products, Commercial managed products, Essential Plan, Medicare, Dual Eligible Special Needs Plan (HMO, D-SNP), and Managed Safety Net Products.

Requests for the drugs on this list are handled by the Medical Specialty Drug unit: Phone 1-800-499-1275 and Fax 1-800-306-0188.

Updates Are Highlighted In Grey

IMPORTANT

> The following Medical Specialty Drugs are covered under the Medical Benefit (when administered by a health care professional) and require preauthorization. Regardless of the preauthorization requirement under the member contract, claims for the following medical specialty drugs will deny or suspend for review across all lines of business if preauthorization is not obtained.

> Please refer to our website frequently for updates to this list as new drugs are added as they receive FDA approval and are available for use.

> The provider or specialty pharmacy rendering the service is responsible for ensuring that the required preauthorization has been obtained.

> Commercial Self Funded Plans: Refer to the Injectable Medications Benefit for coverage details (any coverage exclusions for certain drugs listed with a drug category will be noted under Injectable Medications).

> C-Cross-Over drug is a drug that can be reviewed under the Medical Benefit (Health care professional administered) or Pharmacy Benefit (self- administered). Please note, the prior auth requirements may differ between medical and pharmacy.

> **Avastin injected into the eye does not require a prior authorization
 > ^ Stelara & Skyrizi IV loading doses do not require a prior authorization under the medical benefit. Please obtain prior authorization approval for ongoing SQ therapy PRIOR to administering any IV loading dose(s) to ensure appropriate care for your member.
 * Lemtrada is indicated for relapsing forms of multiple sclerosis only. If seeking treatment with Campath (also alemtuzumab), Campath is no longer commercially available. A restricted distribution program may allow access for appropriate patients. Information is available through the Campath Distribution Program at 1-877-422-2273.

For Genzyme medical information at 1-800-745-4447

> *PIA Program=Medication Assurance Program

